These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

388 related articles for article (PubMed ID: 34322877)

  • 41. The Microbiome and Cancer: Creating Friendly Neighborhoods and Removing the Foes Within.
    Parida S; Sharma D
    Cancer Res; 2021 Feb; 81(4):790-800. PubMed ID: 33148661
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Preferential Expression of Programmed Death Ligand 1 Protein in Tumor-Associated Macrophages and Its Potential Role in Immunotherapy for Hepatocellular Carcinoma.
    Park DJ; Sung PS; Lee GW; Cho S; Kim SM; Kang BY; Hur W; Yang H; Lee SK; Lee SH; Jung ES; Seo CH; Ahn J; Choi HJ; You YK; Jang JW; Bae SH; Choi JY; Yoon SK
    Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33946835
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Targeting the tumor microenvironment to overcome immune checkpoint blockade therapy resistance.
    Li Y; Liu J; Gao L; Liu Y; Meng F; Li X; Qin FX
    Immunol Lett; 2020 Apr; 220():88-96. PubMed ID: 30885690
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Probiotics
    Wang T; Zheng N; Luo Q; Jiang L; He B; Yuan X; Shen L
    Front Immunol; 2019; 10():1235. PubMed ID: 31214189
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Effects of PD-1/PD-L1 signaling pathway on intestinal flora in patients with colorectal cancer.
    Pi H; Huang L; Liu H; Liang S; Mei J
    Cancer Biomark; 2020; 28(4):529-535. PubMed ID: 32568184
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Potential and unsolved problems of anti-PD-1/PD-L1 therapy combined with radiotherapy.
    Cao Y; Li W; Wang Z; Pang H
    Tumori; 2021 Aug; 107(4):282-291. PubMed ID: 32734832
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The Future of Cancer Diagnosis, Treatment and Surveillance: A Systemic Review on Immunotherapy and Immuno-PET Radiotracers.
    Liberini V; Laudicella R; Capozza M; Huellner MW; Burger IA; Baldari S; Terreno E; Deandreis D
    Molecules; 2021 Apr; 26(8):. PubMed ID: 33920423
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Enhancing Checkpoint Inhibitor Therapy in Solid Tissue Cancers: The Role of Diet, the Microbiome & Microbiome-Derived Metabolites.
    Malczewski AB; Ketheesan N; Coward JIG; Navarro S
    Front Immunol; 2021; 12():624434. PubMed ID: 34305883
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Metformin elicits antitumour effect by modulation of the gut microbiota and rescues Fusobacterium nucleatum-induced colorectal tumourigenesis.
    Huang X; Hong X; Wang J; Sun T; Yu T; Yu Y; Fang J; Xiong H
    EBioMedicine; 2020 Nov; 61():103037. PubMed ID: 33039709
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Fusobacterium nucleatum promotes colon cancer progression by changing the mucosal microbiota and colon transcriptome in a mouse model.
    Wu N; Feng YQ; Lyu N; Wang D; Yu WD; Hu YF
    World J Gastroenterol; 2022 May; 28(18):1981-1995. PubMed ID: 35664967
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Dysbiosis of skin microbiome and gut microbiome in melanoma progression.
    Mekadim C; Skalnikova HK; Cizkova J; Cizkova V; Palanova A; Horak V; Mrazek J
    BMC Microbiol; 2022 Feb; 22(1):63. PubMed ID: 35216552
    [TBL] [Abstract][Full Text] [Related]  

  • 52. PD-L1 targeting high-affinity NK (t-haNK) cells induce direct antitumor effects and target suppressive MDSC populations.
    Fabian KP; Padget MR; Donahue RN; Solocinski K; Robbins Y; Allen CT; Lee JH; Rabizadeh S; Soon-Shiong P; Schlom J; Hodge JW
    J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32439799
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Disruption of tumour-associated macrophage trafficking by the osteopontin-induced colony-stimulating factor-1 signalling sensitises hepatocellular carcinoma to anti-PD-L1 blockade.
    Zhu Y; Yang J; Xu D; Gao XM; Zhang Z; Hsu JL; Li CW; Lim SO; Sheng YY; Zhang Y; Li JH; Luo Q; Zheng Y; Zhao Y; Lu L; Jia HL; Hung MC; Dong QZ; Qin LX
    Gut; 2019 Sep; 68(9):1653-1666. PubMed ID: 30902885
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Custom scoring based on ecological topology of gut microbiota associated with cancer immunotherapy outcome.
    Derosa L; Iebba V; Silva CAC; Piccinno G; Wu G; Lordello L; Routy B; Zhao N; Thelemaque C; Birebent R; Marmorino F; Fidelle M; Messaoudene M; Thomas AM; Zalcman G; Friard S; Mazieres J; Audigier-Valette C; Sibilot DM; Goldwasser F; Scherpereel A; Pegliasco H; Ghiringhelli F; Bouchard N; Sow C; Darik I; Zoppi S; Ly P; Reni A; Daillère R; Deutsch E; Lee KA; Bolte LA; Björk JR; Weersma RK; Barlesi F; Padilha L; Finzel A; Isaksen ML; Escudier B; Albiges L; Planchard D; André F; Cremolini C; Martinez S; Besse B; Zhao L; Segata N; Wojcik J; Kroemer G; Zitvogel L
    Cell; 2024 Jun; 187(13):3373-3389.e16. PubMed ID: 38906102
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Microbiota triggers STING-type I IFN-dependent monocyte reprogramming of the tumor microenvironment.
    Lam KC; Araya RE; Huang A; Chen Q; Di Modica M; Rodrigues RR; Lopès A; Johnson SB; Schwarz B; Bohrnsen E; Cogdill AP; Bosio CM; Wargo JA; Lee MP; Goldszmid RS
    Cell; 2021 Oct; 184(21):5338-5356.e21. PubMed ID: 34624222
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Study and analysis of antitumor resistance mechanism of PD1/PD-L1 immune checkpoint blocker.
    Wang Z; Wu X
    Cancer Med; 2020 Nov; 9(21):8086-8121. PubMed ID: 32875727
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Exploring the relationship between intestinal microbiota and immune checkpoint inhibitors in the treatment of non-small cell lung cancer: insights from the "lung and large intestine stand in exterior-interior relationship" theory.
    Li L; Zhong H; Wang Y; Pan Z; Xu S; Li S; Zeng G; Zhang W; Li J; He L
    Front Cell Infect Microbiol; 2024; 14():1341032. PubMed ID: 38415012
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Novel Forms of Immunomodulation for Cancer Therapy.
    Serrano-Del Valle A; Naval J; Anel A; Marzo I
    Trends Cancer; 2020 Jun; 6(6):518-532. PubMed ID: 32460005
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Releasing the brakes of tumor immunity with anti-PD-L1 and pushing its accelerator with L19-IL2 cures poorly immunogenic tumors when combined with radiotherapy.
    Olivo Pimentel V; Marcus D; van der Wiel AM; Lieuwes NG; Biemans R; Lieverse RI; Neri D; Theys J; Yaromina A; Dubois LJ; Lambin P
    J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33688020
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The Influence of Lung Microbiota on Lung Carcinogenesis, Immunity, and Immunotherapy.
    Ramírez-Labrada AG; Isla D; Artal A; Arias M; Rezusta A; Pardo J; Gálvez EM
    Trends Cancer; 2020 Feb; 6(2):86-97. PubMed ID: 32061309
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.